Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
61-80 of 653 trials

Advanced Solid Tumors: ADU-1805 Treatment Study

We are testing a new treatment called ADU-1805 for adults with advanced solid tumors. The study aims to evaluate its safety and how the body handles the medication.

Advanced Cancer1-2 yearsSafety phase (I)Oncology

Aggressive B-cell Non-Hodgkin Lymphoma: Odronextamab Study

We are studying how well odronextamab works compared to standard treatments for adults with previously treated aggressive B-cell non-Hodgkin lymphoma. The trial will also look at safety and how treatment affects daily life.

B-Cell Non-Hodgkin's Lymphoma1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Herpes Zoster Vaccine for Immunocompromised Kids

We are studying a new vaccine for children aged 1 to 17 who have had kidney transplants. The trial will help us understand its safety and how well it triggers an immune response.

Prevention of Shingles in Immunocompromised Children1-2 yearsEfficacy phase (II)No PlaceboCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicinePediatrics

B-Cell Malignancies: CAR-T Cell Therapy Study

We are testing a new CAR-T cell treatment for patients with relapsed and refractory B-cell cancers. The goal is to find a safe dose and understand how well it works.

Diffuse Large B-Cell LymphomaMultiple Myeloma1-2 yearsSafety phase (I)HematologyOncology

Wilson Disease: UX701 Gene Therapy Study

We are evaluating a new gene therapy for adults with Wilson disease to see if it safely helps manage copper levels in the body. The study will also look at how it affects the need for current medications and overall liver health.

Wilson's Disease1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInfectious DiseasesInternal Medicine

Vericiguat for Vasospastic Angina

We are studying how vericiguat affects heart function and angina episodes in patients with vasospastic angina. The trial also looks at quality of life and safety of the treatment.

Vasospastic Angina1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteCardiologyInternal Medicine

Head and Neck Cancer: VB10.16 and Pembrolizumab

We are studying the safety and effectiveness of a new treatment combining VB10.16 with pembrolizumab for patients with HPV16-positive head and neck cancer. This trial aims to find the best dose and evaluate how well this combination works against the cancer.

Head and Neck Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Fabry Disease: PRX-102 for Children and Teens

We are studying the safety and effects of the drug PRX-102 in children and adolescents with Fabry disease. This research aims to understand how well it works and how it is processed in young patients.

Fabry's Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Alzheimer's Disease: PRI-002 Study

We are testing a new medication, PRI-002, for individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease. The study aims to evaluate its safety and effectiveness in improving cognitive function.

Alzheimer's Disease1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Vedolizumab for Kids with Ulcerative Colitis or Crohn’s Disease

We are studying a new injection form of Vedolizumab for children with moderate to severe ulcerative colitis or Crohn’s disease. The goal is to learn about its safety and how it works in the body after initial treatment.

Crohn's DiseaseUlcerative Colitis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Systemic Sclerosis-Associated Lung Disease: Belimumab Study

We are testing whether belimumab can improve lung function and reduce skin thickening in adults with systemic sclerosis-related lung disease. This study compares its effects to a placebo alongside standard treatment.

Systemic Sclerosis Associated Interstitial Lung Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPulmonologyRheumatology

Recurrent Miscarriages: PREMI Trial on Prednisolone

We are studying whether prednisolone can help women with unexplained recurrent miscarriages achieve a live birth. The trial compares this treatment to a placebo and looks at pregnancy outcomes and safety.

Recurrent Miscarriages1-2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Osteogenesis Imperfecta: Romosozumab vs. Bisphosphonates

We are studying whether romosozumab can reduce fractures and improve bone density in children and adolescents with osteogenesis imperfecta compared to bisphosphonates. This trial will help us understand the safety and effectiveness of this new treatment.

Brittle Bone Disease1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyPediatrics

Sjögren’s Syndrome: Deucravacitinib Study

We are testing a new medication, deucravacitinib, for adults with active Sjögren’s Syndrome to see if it improves symptoms better than a placebo. The study also looks at the safety and tolerability of this treatment.

Sjogren's Syndrome1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementRheumatology

Menière's Disease: Methylprednisolone Injection Study

We are investigating whether an injection of methylprednisolone can reduce vertigo attacks in patients with Menière's disease. This study will also assess its effects on hearing and overall quality of life.

Menière's Disease1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteOtolaryngology

Teicoplanin Dosing: Optimized vs. Standard Care

We are studying whether a new dosing method for teicoplanin helps patients achieve better treatment results compared to standard dosing. This trial looks at how quickly patients reach the right drug levels and their overall recovery.

Sepsis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Liver Problems: Study of Vimseltinib

We are investigating how the drug vimseltinib is processed in people with liver problems. This study aims to understand its absorption and effects in this group.

Tenosynovial Giant Cell Tumor (TGCT)Malignant Solid Tumors (MST)1-2 yearsSafety phase (I)HepatologyOncology

Cholestatic Pruritus: Linerixibat Treatment Study

We are studying the long-term safety and tolerability of linerixibat for people with cholestatic pruritus due to primary biliary cholangitis. The trial also looks at how this treatment affects quality of life and itch relief.

Cholestatic PruritusPrimary Biliary Cholangitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyHepatology

Hereditary Angioedema: OCTA-C1-INH Treatment Study

We are studying a new intravenous treatment for people with hereditary angioedema to see if it effectively relieves symptoms during acute attacks. The trial includes adolescents and adults, and also looks at safety and quality of life.

Hereditary Angioedema1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyHematology

Pulmonary Arterial Hypertension: Seralutinib Inhalation Study

We are studying whether inhaling seralutinib helps improve exercise capacity in people with pulmonary arterial hypertension. The trial also looks at safety and other health benefits compared to a placebo.

Pulmonary Arterial Hypertension1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyPulmonology